TORONTO, Jan. 23, 2012 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases including Alzheimer's disease and ALS today announced that it has agreed to participate in a neuroscience partnering trade mission to Europe organized by the Department of Foreign Affairs and International Trade (DFAIT). The mission will include a series of special meetings for Canadian companies and institutions involved in neuroscience research, development, commercialization and clinical practice, with an emphasis on innovative technologies and approaches for diagnosis, monitoring and treatment of neurodegenerative conditions affecting the brain.
Amorfix's Chief Scientific Officer, Dr. Neil Cashman, has been invited by DFAIT to speak about the important work the company is doing in Alzheimer's disease and ALS and to discuss the company's portfolio of neuroscience projects available for partnering with the attendees of these by-invitation-only meetings.
The meetings will take place in London and Paris between January 23 and 27, 2012 and will include key European companies, institutions and agencies with interest and capacity to partner with Canadian organizations. The objective is to connect Canadian participants to opportunities for financing/funding, scientific exchange, collaborative R&D, licensing, service agreements and distribution with major European and international pharmaceutical and medical device companies, research institutions and funding agencies with substantial interests in the neurodegenerative disease field.
"Part of our business strategy is to form strategic alliances and partnerships with other pharmaceutical companies around our protein misfolding discovery platform and product portfolio, including an Alzheimer's disease diagnostic and immunotherapies for common cancers", said Dr. Robert Gundel, Amorfix President and CEO. "The DFAIT European meetings will provide an opportunity to establish such partnerships."
Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Cancer immunotherapies have in the past been directed against targets which are also present on normal cells, whereas Amorfix's innovative ProMIS platform identifies targets present only on cancer cells, retaining efficacy with improved safety. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS, as well as AD and ALS diagnostic tests. Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation and the development of a human screening test for AD and a blood test to diagnose ALS. For more information about Amorfix, visit www.amorfix.com.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information: